Author Response
Authors' Response
Abstract
To the Editor: In our article we found that the prevalence of eosinophilia in our cohort of ART (antiretroviral therapy)-naïve patients infected with the human immunodeficiency virus (HIV) was 9.7%.1 This is slightly higher than similar rates reported in other studies performed in developed countries (Switzerland 6.3%,2 the Netherlands 6.3%,3 and the United States 5.5%4). Studies in developing countries showed much higher rates of eosinophilia in HIV-infected patients (Brazil 18%,5 Zimbabwe 23.5%,6 and Venezuela 28.2%7). In addition, a study in the United Kingdom by Sivaram et al demonstrated a rate of 19.5%; however, most of the patients in that study were from developed countries or had resided there for an extended period (58%).8This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.